WHO ICTRP trial
The effect of spironolactone in treatment of heart failure
IRCT2015101924597N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT2015101924597N1 |
|---|---|
| Public title | The effect of spironolactone in treatment of heart failure |
| Scientific title | The effect of spironolactone on the clinical characteristics, laboratory, and echocardiography in patients with heart failure Preserved EF |
| Primary sponsor | Vice chancellor for research of Iran university of medical sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Heart Failure. Congestive heart failure;Congestive heart failure |
| Interventions | Intervention 1: In the intervention group spironolactone tablets (tablets 25 mg pharmaceutical company Mino) at a dose of 12.5 mg daily after two weeks if there is no increase in creatinine and potassium is increased to 25 mg daily… |
| Registration date | Jan 29, 2016 |
| Target size | 60 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: